To provide a mirror-type fusion device capable of stably confining high-density plasma. The mirror-type fusion device includes: a central chamber 10; a confining magnetic field generating unit 20; and a plasma generating unit 30. The central chamber 10 extends in the longitudinal direction for confining plasma. The confining magnetic field generating unit 20 includes at least two coils 21 and 21 arranged coaxially with a longitudinal axis of the central chamber 10 so as to face each other and is configured to generate a confining magnetic field 22 for confining plasma in a region between the two coils 21 and 21. The plasma generating unit 30 is connected to the central chamber 10 at a position between the two coils 21 and 21 of the confining magnetic field generating unit 20 and configured to rapidly form a high-density plasma region in the confining magnetic field 22.
G21B 1/05 - Réacteurs de fusion thermonucléaire avec confinement magnétique ou électrique du plasma
H05H 1/14 - Dispositions pour confiner le plasma au moyen de champs électriques ou magnétiquesDispositions pour chauffer le plasma utilisant uniquement des champs magnétiques appliqués dans lesquels l'enceinte est droite et comporte un miroir magnétique
2.
THREE-DIMENSIONAL PRINTING APPARATUS, THREE-DIMENSIONAL PRINTING METHOD, AND COMPRESSION APPARATUS
In a three-dimensional printing apparatus, a printing material (F) supplied from a nozzle (64) is disposed along a printing path, and a sheet-like material layer (FL) configured with a single layer or a plurality of layers is formed. The material layer (FL) is compressed by a heating member (81) while performing relative movement between a table (3) and the heating member (81).
B29C 64/194 - Procédés de fabrication additive impliquant des opérations supplémentaires effectuées sur les couches ajoutées, p. ex. lissage, meulage ou contrôle d’épaisseur pendant l’empilage des couches
An image processing apparatus that includes a storage storing image data obtained by CT imaging of dentition constituent tissue, a processor, and a display. The processor generates three-dimensional image data of the dentition constituent tissue, identifies a segmentable region in the dentition constituent tissue, identifies a three-dimensional position of the segmentable region, generates a dentition developed image, identifies a segmentable region corresponding position corresponding to the three-dimensional position in the dentition developed image, and displays, on the display, the dentition developed image in which the segmentable region is displayed at the segmentable region corresponding position. By designation of the segmentable region corresponding position, on the basis of a correspondence between the segmentable region corresponding position and the three-dimensional position, a detail observation image of the segmentable region is generated, and a detail observation reference position is determined according to a predetermined rule.
A61B 6/46 - Agencements pour l’interface avec l’opérateur ou avec le patient
A61B 6/51 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques à la technique dentaire
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
5.
IMAGE PROCESSING APPARATUS, IMAGE PROCESSING METHOD, AND STORAGE MEDIUM
An image processing apparatus having a processor and a display that displays an observation image. The processor generates three-dimensional image data of the dentition constituent tissue, detects a biological feature region in the dentition constituent tissue, identifies a three-dimensional position, generates a dentition developed image in which the dentition constituent tissue is developed, identifies a biological feature region corresponding position corresponding to the three-dimensional position in the dentition developed image, displays, on a display, a biological feature region arrangement developed image in which an annotation image indicating the biological feature region is superimposed on the dentition developed image such that the annotation image is located at the biological feature region corresponding position, generates a detail observation image at the three-dimensional position on the basis of the three-dimensional image data, and displays the detail observation image simultaneously with the biological feature region arrangement developed image on the display.
This catalyst is for use in condensation of a carboxylic acid and an amine compound having an amino group or a substituted amino group in which one hydrogen atom in the amino group is substituted with a substituent. The catalyst comprises a compound represented by general formula (1) (in the formula, R1, R2, R3, and R4each independently represent a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a nitro group, an amino group, a sulfo group, an alkyl group, or an acyl group, and X1 represents a hydrogen atom, a silyl-based protecting group, a sulfonyl-based protecting group, an alkyl group, an alkenyl group, an aralkyl group, or an acyl group). This amide compound production method comprises a step for obtaining an amide compound through condensation of the carboxylic acid and the amine compound by using the catalyst.
C07C 231/02 - Préparation d'amides d'acides carboxyliques à partir d'acides carboxyliques ou à partir de leurs esters, anhydrides ou halogénures par réaction avec de l'ammoniac ou des amines
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
C07C 233/65 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone de radicaux hydrocarbonés non substitués
C07C 235/34 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
C07F 7/10 - Composés comportant une ou plusieurs liaisons C—Si azotés
7.
HEAD FOR THREE-DIMENSIONAL PRINTING DEVICE, NOZZLE FOR THREE-DIMENSIONAL PRINTING DEVICE, THREE-DIMENSIONAL PRINTING DEVICE, AND THREE-DIMENSIONAL PRINTING METHOD
This head for a three-dimensional printing device is provided with a first portion (11), a second portion (13), and a window (14). The first portion (11) has a first wall (112) facing a reference axis (AX1). The second portion (13) has a second wall (132) facing the reference axis (AX1) and a tip surface (135) intersecting the reference axis (AX1). A resin filament is pressed between the tip surface (135) and a target. The window (14) allows physical access and/or contactless energy transfer to an object or space located between the first wall (112) of the first portion (11) and the tip surface (135) of the second portion (13).
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
B29C 64/268 - Agencements pour irradiation par faisceaux laserAgencements pour irradiation par faisceaux d’électrons [FE]
SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION (Japon)
Inventeur(s)
Sahara, Hiroeki
Nakayama, Tomohiro
Maruo, Takuya
Abrégé
There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
A diagnosis assistance device receives an automatically quantified value of myocardial ischemia, and cardiac function information and phase information acquired by performing stress myocardial scintigraphy and acquires and outputs at least one of a reperfusion therapy prediction result, a heart failure onset prediction result, a cardiac death prediction result, an all-cause mortality prediction result, and a coronary artery disease prediction result on the basis of the automatically quantified value of the myocardial ischemia, the cardiac function information, the phase information, and a trained model. The trained model is obtained by performing machine learning on a relationship between a combination of the automatically quantified value of the myocardial ischemia, the cardiac function information, and the phase information and at least one of the reperfusion therapy result, the heart failure onset prediction result, the cardiac death prediction result, the all-cause mortality prediction result, and the coronary artery disease prediction result.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
A sleep respiration improvement apparatus (1) comprises: a pharyngeal stimulation device (2b) that selectively stimulates a pharyngeal part; and a mouthpiece (2a) that can be worn in the oral cavity and supports the pharyngeal stimulation device (2b).
A61F 5/56 - Dispositifs pour prévenir le ronflement
A61H 23/02 - Massage par percussion ou vibration, p. ex. en utilisant une vibration ultrasoniqueMassage par succion-vibrationMassage avec des membranes mobiles à entraînement électrique ou magnétique
The present invention provides a mirror fusion device capable of stably confining high-density plasma. This mirror fusion device comprises a central vessel 10, a confining magnetic field configuration generation unit 20, and a plasma generation unit 30. The central vessel 10 extends in a longitudinal direction to confine plasma. The confining magnetic field configuration generation unit 20 comprises at least two coils 21, 21 disposed opposite one another and coaxially with the longitudinal direction of the central vessel 10, and generates a confining magnetic field 22 for confining the plasma between the two coils 21, 21. The plasma generation unit 30 is connected to the central vessel 10 between the two coils 21, 21 of the confining magnetic field configuration generation unit 20, and rapidly forms a high-density plasma region inside the confining magnetic field 22.
H05H 1/14 - Dispositions pour confiner le plasma au moyen de champs électriques ou magnétiquesDispositions pour chauffer le plasma utilisant uniquement des champs magnétiques appliqués dans lesquels l'enceinte est droite et comporte un miroir magnétique
G21B 1/05 - Réacteurs de fusion thermonucléaire avec confinement magnétique ou électrique du plasma
Provided are a simple and highly accurate sample test method, which is capable of being applied to an evaluation of the presence or absence of one or more selected from the group consisting of a gynecological cancer and a precancerous lesion thereof, an evaluation of prognosis of a gynecological cancer patient, or an evaluation of a degree of malignancy of the gynecological cancer, a test kit capable of being used for the test method, and a medicine for treating or preventing a gynecological cancer, which is to be administered to a subject detected by the test method.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
13.
PARTICLE-AGGREGATION-PROMOTING DEVICE AND DUST COLLECTOR
This particle-aggregation-promoting device (3) comprises: a vibrating element (10); a plurality of flat plates (12) arranged in parallel with each other; a single screw shaft (11) linking the vibrator (10) and the flat plates (12) between the vibrating element (10) and the flat plates (12); and nuts (13) for linking the flat plates (12) to the screw shaft (11) at discretionary positions on the screw shaft (11).
Provided is an immunogenic carrier comprising a protein and an amino polysaccharide that contains 100 or more amino groups per molecule. Also provided is an immunogenic composition comprising the immunogenic carrier and a short-chain peptide.
A61K 39/385 - Haptènes ou antigènes, liés à des supports
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
This method for producing fine particles includes: a step for forming a polyion complex by ion-bonding an ionic active material and an ionic polymer; and a step for forming fine particles which contain the polyion complex and at least one polymer (P) that is selected from among a polylactic acid and a lactic acid-glycolic acid copolymer. The step for forming fine particles includes: a step for mixing the polyion complex and the polymer (P) in an organic solvent; a step for forming an o/w emulsion by adding the organic solvent after mixing, the organic solvent containing the polyion complex and the polymer (P), to an aqueous solution in which a dispersant for preventing bonding between emulsions is dissolved; and a step for removing the organic solvent from the aqueous solution that contains the o/w emulsion.
The present disclosure provides a method to determine whether or not a patient has received administration of a direct oral anticoagulant (DOAC). The present disclosure provides a method comprising allowing magnetic particles in a reagent to move after the addition of a sample to a dry reagent containing magnetic particles, monitoring the movement signal of the magnetic particles, analyzing the monitored movement signal of the magnetic particles, and comparing the results of analysis with a threshold, and a program and an apparatus used for such method.
G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
17.
DRAW SOLUTION, WATER TREATMENT METHOD, AND WATER TREATMENT APPARATUS
A draw solution contains a polymeric compound produced using, as starting materials, a compound represented by general formula (a) and a compound represented by general formula (b) as a draw solute.
A draw solution contains a polymeric compound produced using, as starting materials, a compound represented by general formula (a) and a compound represented by general formula (b) as a draw solute.
[In formula (a) and formula (b), R1 and R2 each independently represent a hydrogen atom or a methyl group.]
B01D 61/00 - Procédés de séparation utilisant des membranes semi-perméables, p. ex. dialyse, osmose ou ultrafiltrationAppareils, accessoires ou opérations auxiliaires, spécialement adaptés à cet effet
C02F 1/44 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par dialyse, osmose ou osmose inverse
C08F 226/02 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison simple ou double à l'azote ou par un hétérocycle contenant de l'azote par une simple ou une double liaison à l'azote
18.
MUCOSAL ADJUVANT AND METHOD FOR MANUFACTURING MUCOSAL ADJUVANT
[Problem] To provide a highly efficient mucosal adjuvant that can be safely administered to humans. [Solution] A mucosal adjuvant comprises bioapatite and is characterized in that low-sulfate bioapatite using calcined eggshells is included and that the antigenicity of solid membrane vesicles secreted by Streptococcus mutans is enhanced by the low-sulfate bioapatite. With this configuration, the low-sulfate bioapatite, being a component of bones and teeth, can be safely administered to humans and is easily taken up by dendritic cells, which are antigen-presenting cells, due to the very small particle size of approximately 20 nm, thereby providing a highly efficient mucosal adjuvant.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
The present invention provides an ultrasonic vibration generation device the total length of which can be freely adjusted. An ultrasonic vibration body (3) comprises: a vibrator connection part (4) to which a vibrator unit (2) is connected; a conical horn (5) for converting at least a part of vertical vibration transmitted via the vibrator connection part 4 into lateral vibration having mutually different directions and sizes; and a columnar vibration part (6) which is provided so as to protrude from the conical horn (5) with the root thereof connected to the conical horn (5), and in which the tip is ultrasonically vibrated in a plane orthogonal to the traveling direction of the vertical vibration as the lateral vibration is transmitted.
B06B 1/02 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique
An ultrasonic projection device for projecting ultrasonic waves includes a first block body, a second block body, and a piezoelectric unit sandwiched between the first block body and the second block body. A vibration plate is provided at one end on the first block body side in the axial direction of the first block body, the second block body, and the piezoelectric unit. The dimension from the one end to the other end on the second block body side in the axial direction approximately coincides with half of the wavelength of vibration generated by the piezoelectric unit. A connection portion having a groove with a smooth inner wall surface which connects the vibration plate and a base portion is provided between the vibration plate and the base portion which supports the vibration plate.
G10K 9/122 - Dispositifs dans lesquels le son est produit par la vibration d'un diaphragme ou un élément analogue, p. ex. cornes de brume, avertisseurs de véhicule ou vibreurs fonctionnant électriquement utilisant des moyens d'entraînement piézo-électriques
A composition for absorbing carbon dioxide including an ionic liquid (A) containing a cation and an anion, and a protic compound (B) having a relative permittivity at 25° C. of 20 or more, wherein the cation at least includes a cation represented by the formula (1), the anion includes an anion where an acid dissociation constant (pKa) at 25° C. of its conjugate acid in water is 4.5 or more, and the ratio of a value obtained by multiplying the number of hydroxyl groups of the protic compound (B) by the number of moles of the protic compound (B) to the number of moles of the ionic liquid (A) [number of moles of protic compound (B)/number of moles of ionic liquid (A)] is 0.2 to 1.0:
2 each independently represent a hydrogen or a C1-C6 linear alkyl group.
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
22.
PAIN DETERMINATION DEVICE, PAIN DETERMINATION METHOD, AND PROGRAM
This pain determination device comprises: a first response data acquisition unit that acquires first response data including a combination of responses by a first patient to first questions about at least one of the type of sensation of a pain which is somatic pain, the intensity of the pain, the frequency of the pain, or triggers of the pain, and responses about the first patient to second questions about at least one of psychological factors, social factors, health status, or lifestyle; and a determination unit that, on the basis of a trained model trained on the relationship between second response data, including a combination of responses by a second patient to the first questions and responses about the second patient to the second questions, and the type of cause of the pain of the second patient, determines at least one of the type of the cause of the pain of the first patient from the first response data acquired by the first response data acquisition unit, or the degree of importance of each explanatory variable, included in the first response data, to the type of the cause of the pain of the first patient.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
23.
METHOD AND KIT FOR PREDICTING EFFICACY OF TREATMENT WITH IMMUNOTHERAPEUTIC AGENT ON PATIENT WITH MUCOSAL LESION
The present invention provides a novel method and kit for predicting the efficacy of treatment with an immunotherapeutic agent on a patient with a mucosal lesion. The present invention is a method for predicting the efficacy of treatment with an immunotherapeutic agent on a patient with a mucosal lesion, the method comprising a step for measuring the expression level of CD86 in a biological sample derived from a patient with a mucosal lesion. The present invention is a kit for use in the above method, the kit comprising a substance that binds specifically to CD86, or forward and reverse primers for amplifying nucleic acids encoding CD86.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
24.
PHARMACEUTICAL COMPOSITION FOR PREVENTING PROLIFERATIVE VITREORETINOPATHY CONTAINING AUTOTAXIN APTAMER
The present invention addresses the problem of providing a novel pharmaceutical composition for preventing proliferative vitreoretinopathy. The present invention solves the problem by providing a pharmaceutical composition for preventing proliferative vitreoretinopathy, comprising an autotaxin aptamer or a salt thereof.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
C25B 15/08 - Alimentation ou vidange des réactifs ou des électrolytesRégénération des électrolytes
26.
DIAGNOSIS ASSISTANCE DEVICE, LEARNING MODEL CREATION DEVICE, DIAGNOSIS ASSISTANCE METHOD, LEARNING MODEL CREATION METHOD, AND PROGRAM
This diagnosis assistance device accepts myocardial ischemia automatic quantitative values, and cardiac function information and phase information acquired by implementing cardiac stress scintigraphy; and, on the basis of the myocardial ischemia automatic quantitative values, the cardiac function information, the phase information, and a trained model, the diagnosis assistance device acquires and outputs at least one from among a reperfusion therapy prediction result, a heart failure onset prediction result, a cardiac death prediction result, a total mortality prediction result, and a coronary artery disease prediction result. The trained model is obtained by training the model with the relationship between: a combination of myocardial ischemia automatic quantitative values, cardiac function information, and phase information; and at least one from among the reperfusion therapy result, the heart failure onset prediction result, the cardiac death prediction result, the total mortality prediction result, and the coronary artery disease prediction result.
A stable isotope-labeled indole carboxylic acid compound represented by Formula (I) is provided. In Formula (I), X1 to X8 are each independently C or 13C; Y is N or 15N; M is H, Na, K, Li, CH3, or C2H5; R1 is H or D; R2 is H, CH3, 13CH3, C2H5, or 13C2H5; R3 is H, CH3, 13CH3, C2H5, or 13C2H5; R4 is H or D; and R5 is H or D.
A stable isotope-labeled indole carboxylic acid compound represented by Formula (I) is provided. In Formula (I), X1 to X8 are each independently C or 13C; Y is N or 15N; M is H, Na, K, Li, CH3, or C2H5; R1 is H or D; R2 is H, CH3, 13CH3, C2H5, or 13C2H5; R3 is H, CH3, 13CH3, C2H5, or 13C2H5; R4 is H or D; and R5 is H or D.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C07D 209/42 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
G01N 33/96 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
28.
SAMPLE TEST METHOD, TEST KIT FOR GYNECOLOGICAL CANCER AND PRECANCEROUS LESION THEREOF, AND MEDICINE
Provided are: a simple and highly accurate sample test method which can be applied to the evaluation of the presence or absence of at least one selected from the group consisting of a gynecological cancer and a precancerous lesion thereof, the evaluation of the prognosis of a gynecological cancer patient, or the evaluation of the degree of malignancy of a gynecological cancer; a test kit which can be used for the test method; and a medicine for treating or preventing a gynecological cancer, which is intended to be administered to a subject detected by the test method. A sample test method is employed, the method comprising a step (A) for measuring the concentration of a free fatty acid in a sample from a subject and a step (B) for evaluating the possibility that the subject would have a of gynecological cancer on the basis of the concentration of the free fatty acid obtained in the step (A).
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
29.
THREE-DIMENSIONAL PRINTING APPARATUS, THREE-DIMENSIONAL PRINTING METHOD, AND COMPRESSION APPARATUS
In this three-dimensional printing apparatus, a print material (F) supplied from a nozzle (64) is arranged along a print path to form a sheet-like material layer (FL) composed of a single layer or a plurality of layers. The material layer (FL) is compressed by a heating member (81) as a table (3) and the heating member (81) move relative to each other.
B33Y 30/00 - Appareils pour la fabrication additiveLeurs parties constitutives ou accessoires à cet effet
B33Y 50/02 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
B29C 64/188 - Procédés de fabrication additive impliquant des opérations supplémentaires effectuées sur les couches ajoutées, p. ex. lissage, meulage ou contrôle d’épaisseur
A method for producing an acidic gas absorbent containing a compound represented by general formula (1), the method comprising a step for mixing: a composition mixture of an acidic gas and a compound represented by general formula (1); and at least one protic solvent selected from the group consisting of water and alcohols having 1-3 carbon atoms and optionally having a substituent group. [In general formula (1), R1-R4each independently represent a hydrogen atom or an alkyl group having 1-6 carbon atoms, and X- represents an anion of a saturated aliphatic monocarboxylic acid having 2-6 carbon atoms.]
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
This method for producing human dedifferentiated fat cells comprises a step for culturing human mature fat cells using a culture medium containing human platelet lysate. This culture medium for producing human dedifferentiated fat cells from human mature fat cells contains human platelet lysate.
This quantum tomographic imaging device, which uses an optical element having a quantum pulse gate characteristic to acquire tomographic image information at a desired depth in a biological sample: emits a probe light pulse onto the biological sample and acquires a reflected light pulse thereof; includes a delay unit for imparting a delay to a pulse for pump light, and a waveform shaping unit for performing waveform shaping of the pulse for pump light; generates a pump light pulse as a result of the delay and the waveform shaping; combines the reflected light pulse and the pump light pulse to generate a combined light pulse thereof; inputs the combined light pulse into the optical element; and, by utilizing a quantum pulse gate characteristic of the optical element, employs a single-photon detector to detect an upward converted signal light pulse obtained as a result of an upward conversion of a frequency of a desired signal light pulse contained in the combined light pulse.
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
G01B 11/24 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer des contours ou des courbes
G01J 11/00 - Mesure des caractéristiques d'impulsions lumineuses individuelles ou de trains d'impulsions lumineuses
This ultrasonic projection device 1 for projecting ultrasonic waves comprises a first block body 2, a second block body 3, and a piezoelectric unit 4 clamped by the first block body 2 and the second block body 3. A vibration plate 6b is provided on one end on the first block body 2 side in the axial direction of the first block body 2, the second block body 3, and the piezoelectric unit 4. The dimension from the one end in the axial direction to the other end on the second block body 3 side is formed so as to approximately equal to a half wavelength of the vibration generated by the piezoelectric unit 4. A connection part 6c, in which a groove part 6e having a smooth inner wall surface 6e1 that connects the vibration plate 6b and the base part 6a is formed, is provided between the vibration plate 6b and a base part 6a that supports the vibration plate 6b.
H04R 17/10 - Transducteurs résonnants, c.-à-d. adaptés pour produire une puissance de sortie maximum pour une fréquence déterminée
B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
34.
DRAW SOLUTION, WATER TREATMENT METHOD, AND WATER TREATMENT APPARATUS
For the purpose of providing a draw solution containing an UCST-type polymeric compound useful as a draw solute in a forward osmosis membrane separation method for performing the membrane separation of water using a forward osmosis membrane, a water treatment method and a water treatment apparatus, the draw solution contains a polymeric compound produced using, as starting materials, a compound represented by general formula (a) and a compound represented by general formula (b) as a draw solute. [In formula (a) and formula (b), R1and R2 each independently represent a hydrogen atom or a methyl group.]
B01D 61/00 - Procédés de séparation utilisant des membranes semi-perméables, p. ex. dialyse, osmose ou ultrafiltrationAppareils, accessoires ou opérations auxiliaires, spécialement adaptés à cet effet
The purpose of the present invention is to provide a means for inhibiting intestinal absorption of β-alanine. This problem can be solved by the β-alanine absorption inhibitor of the present invention that comprises, as an active ingredient, a compound selected from the group consisting of γ-aminobutyric acid, taurine, glycine, lysophosphatidylcholine and α-glycerophosphocholine, or a salt thereof.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/185 - AcidesLeurs anhydrides, halogénures ou sels, p. ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
36.
METHOD FOR MANUFACTURING MOLDED ARTICLE WITH MOLDING DIE PRODUCED BY 3D PRINTER AND MOLDED ARTICLE
[Problem] To provide: a fabric-reinforced thermoplastic resin sheet molded article in which a corner part is not extremely thinned or bored, a curved part has a beautiful finished feeling without a disorder of fabric arrangement appearing on a surface of the molded article, and a fabric-reinforced thermoplastic resin sheet does not cause interlayer delamination during molding; and a manufacturing method for efficiently manufacturing the molded article. [Solution] Provided are: a method for manufacturing a fabric-reinforced thermoplastic resin sheet molded article characterized in that a fabric-reinforced thermoplastic resin sheet is vacuum-molded using a molding die having countless micropores produced by a thermally melting lamination method (3D printer) as a female die or a male die or as a female die and a male die; and a fabric-reinforced thermoplastic resin sheet molded article obtained by vacuum-molding a fabric-reinforced thermoplastic resin sheet and characterized by using a molding die having countless micropores produced by a thermally melting lamination method that is one of molding dies for vacuum molding as a female die or a male die or as a female die and a male die.
B29C 51/08 - Emboutissage profond ou façonnage dans des moules en deux parties, c.-à-d. en utilisant uniquement des moyens mécaniques
B29C 51/14 - Façonnage par thermoformage, p. ex. façonnage de feuilles dans des moules en deux parties ou par emboutissage profondAppareils à cet effet de préformes ou de feuilles multicouches
B29K 105/08 - Présentation, forme ou état de la matière moulée contenant des agents de renforcement, charges ou inserts de grande longueur, p. ex. ficelles, mèches, mats, tissus ou fils
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
B29C 33/38 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la matière ou le procédé de fabrication
B29C 70/22 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant uniquement des renforcements, p. ex. matières plastiques auto-renforçantes des renforcements fibreux uniquement caractérisées par la structure des renforcements fibreux utilisant des fibres de grande longueur, ou des fibres continues orientées dans au moins deux directions formant une structure bidimensionnelle
B29C 70/42 - Façonnage ou imprégnation par compression pour la fabrication d'objets de longueur définie, c.-à-d. d'objets distincts
A composition for carbon dioxide absorption comprising an ionic liquid (A) comprising one or more cations and an anion and a protonic compound (B) having a relative permittivity at 25°C of 20 or greater, wherein at least one of the cations is represented by general formula (1), the anion is one, the conjugate acid of which has an acid dissociation constant (pKa) in water at 25 degrees of 4.5 or greater, and the proportion of the number of moles of the protonic compound (B) multiplied by the number of hydroxyl groups of the protonic compound (B) to the number of moles of the ionic liquid (A), (number of moles of the protonic compound (B))/(number of moles of the ionic liquid (A)), is 0.2-1.0. [In general formula (1), R1and R2 each independently represent a hydrogen atom or a C1-C6 chain alkyl group.]
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
NATIONAL AGENCY FOR AUTOMOBILE AND LAND TRANSPORT TECHNOLOGY (Japon)
Inventeur(s)
Tsunashima Hitoshi
Takata Tetsuya
Ogino Masayuki
Sato Yasuhiro
Ogata Seigo
Abrégé
An information processing device comprising: a first generation unit that uses waveforms for waves indicating changes in track displacement between a start point on a first track traveled by rolling stock to an end point on the first track, using the waveforms as track displacement waveforms, and generates a plurality of track displacement waveforms that are different from each other; a second generation unit that generates a vibration waveform, being a waveform for a wave that indicates the change in vibration expected to be generated between the start point and the end point, in a rolling stock that travels virtually along the first track, when the shape of a waveform indicating track displacement on the first track from the start point to the end point does not match the waveform indicated by the track displacement waveform, generating same for each of the plurality of track displacement waveforms generated by the first generation unit; and a third generation unit that generates correspondence information that indicates the correlation between the size of the track displacement and the size of the vibration, on the basis of the plurality of track displacement waveforms generated by the first generation unit and the vibration waveforms generated by the second generation unit for each of the plurality of track displacements.
Provided are novel determination techniques and systems enabling an AI process in which decisions are made from the viewpoint of allowing an expert to make a decision, and capable of providing a valid answer, even with a small amount of learning data, by adjusting errors in both the answer of the expert and the answer of AI. A system is configured to cause an AI process to be performed on subject teacher data for AI learning in which events of objects identified by identifying codes are divided into classes, and data pertaining to an object for which class determination of an event is required, and to receive class determination data obtained by the AI process. The system is configured to: cause teacher data for learning to be randomly input to, and learned by, each of a plurality of AI processes; input data pertaining to the object into each of the plurality of AI processes; receive from each AI process class determination data corresponding to each learning; and store the class determination data in a storage device. In this way, the class of an event of an object identified by each identifying code is determined on the basis of each class determination data item corresponding to the identifying code.
A plasmid transfection agent that comprises a peptide containing an amino acid sequence represented by SEQ ID NO: 1. SEQ ID NO: 1: CXDXXXXYXC (wherein: X represents an arbitrary amino acid residue; C represents cysteine; D represents aspartic acid; and Y represents tyrosine.)
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
The present invention has an object of providing a composition that is effective for the treatment of a prototheca disease. According to the present invention, a composition containing ravuconazole as an active ingredient, which is administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii, is provided.
A panoramic X-ray imaging apparatus includes: an X-ray generating unit; an X-ray detecting unit; a support that supports the X-ray generating unit and the X-ray detecting unit; a drive mechanism that turns at least the X-ray generating unit and the X-ray detecting unit by driving the support; a displacement mechanism that adds movement including a displacement component in a direction different from the turning to the X-ray detecting unit; a subject holding unit that holds an imaging subject; a turning controller that controls the turning by a drive mechanism and the displacement mechanism. The turning controller controls the drive mechanism and the displacement mechanism so as to add the movement avoiding the contact with the shoulder of the imaging subject during the turning of the X-ray generating unit and the X-ray detecting unit by the drive mechanism during the panoramic X-ray imaging.
A61B 6/14 - Applications ou adaptations à l'art dentaire
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 6/40 - Agencements pour générer des radiations spécialement adaptés au diagnostic par radiations
A61B 6/42 - Agencements pour détecter des radiations spécialement adaptés au diagnostic par radiations
43.
METHOD AND SYSTEM USING ACOUSTIC INFORMATION OBTAINED FROM A JOINT AS AN INDICATOR OF A JOINT STATE
The problem to be solved is to provide a new method and system for appropriately detecting a joint state from an acoustic of a joint. The present method comprises the step of obtaining, using a bio-acoustic sensor, an acoustic signal emitted by a joint during a time period that at least includes a first motion period wherein the joint changes from a first state to a second state, a pause period of the joint and a second motion period wherein the joint changes from the second state to the first state, the step of converting the obtained acoustic signal into time trend data that at least shows a relationship between an acoustic signal intensity and time, and the step of setting, from the time trend data, a basic threshold value regarding the acoustic signal intensity to calculate first acoustic information based on the basic threshold value, characterized in that the first acoustic information is an indicator of the joint state.
A jaw movement analysis system includes circuitry that is configured to acquire chewing information including time-series information that represents a jaw movement of a user chewing a bite of food, and to determine an attribute of the food having been chewed by the user based on the chewing information acquired and based on an analysis model. The analysis model is generated by machine learning based on training data including first information that includes time-series information indicating a past jaw movement during a chewing of a bite of food, and second information that indicates an attribute of the food chewed during the past jaw movement associated with the first information.
The purpose of the present invention is to provide a modified milk protein that has high solubility in an acidic region, excellent foaming properties and high safety, and a method for producing the milk protein while minimizing the risk of exposure to hydrolysis. This purpose can be solved by, for example, a method for producing deamidated casein that comprises a step for subjecting a casein-containing suspension to a deamidation reaction using a weakly acidic cation exchange resin, which has an alkali metal salt-type ion exchange group, for 4-50 hours at 40-90°C to thereby give deamidated casein having a deamidation ratio of 14% or more and less than 32%.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A method of producing induced pluripotent stem cells including a step for introducing an initialization factor into somatic cells of a mammal, and culturing in a neural stem cell culture medium to obtain induced neural stem cell-like cells, and a step for cultivating said induced neural stem cell-like cells in a growth medium to obtain induced pluripotent stem cells, wherein the initialization factor contains an OCT family, a SOX family, a KLF family, a MYC family, a LIN28 family and a P53 function inhibitor.
The present invention employs the following method for determining the tolerance of a Trichophyton fungus to a squalene epoxidase inhibitor. This method comprises: step (a) for, using genomic DNA of a target Trichophyton fungus as a template, conducting a nucleic acid amplification reaction with the use of a primer comprising the base sequence represented by SEQ ID NO: 1 and a primer comprising the base sequence represented by SEQ ID NO: 2 to obtain a squalene epoxidase gene fragment; step (b) for analyzing the base sequence of the squalene epoxidase gene fragment; and step (c) for, when a deduced amino acid sequence of the squalene epoxidase of the target Trichophyton fungus has a Leu393Phe mutation and/or a Phe397Leu mutation, then determining that the target Trichophyton fungus has tolerance to a squalene epoxidase inhibitor.
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
C12N 15/31 - Gènes codant pour des protéines microbiennes, p. ex. entérotoxines
A nucleic acid detection kit including: (i) a first single-stranded circular DNA; (ii) a first oligonucleotide primer; (iii) a second single-stranded circular DNA; and (iv) a second oligonucleotide primer; wherein the first oligonucleotide primer is hound to a carrier through the 5′-end thereof, and the second oligonucleotide primer is bound, through the 5′-end thereof, to the carrier to which the first oligonucleotide primer is hound.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12Q 1/6853 - Réactions d’amplification d’acides nucléiques utilisant des amorces ou des matrices modifiées
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
C12Q 1/6834 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide
C07D 277/66 - Benzothiazoles avec uniquement des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués liés en position 2 avec des cycles ou des systèmes cycliques aromatiques liés directement en position 2
49.
METHOD FOR FIXING CARBON DIOXIDE TO CONCRETE, AND CONCRETE STRUCTURE INCLUDING CONCRETE
Provided is a method for efficiently fixing carbon dioxide to concrete. The method includes: forming a gas injection hole in concrete included in a concrete structure; introducing a gas containing carbon dioxide into the gas injection hole; and after introducing the gas containing carbon dioxide, capping one end of the gas injection hole to seal the gas including carbon dioxide in the gas injection hole. The method may further include decompressing the gas injection hole before the introduction of the gas including carbon dioxide. The gas including carbon dioxide may further include water.
E04C 3/20 - PoutrellesSolives, fermes ou structures analogues à des fermes, p. ex. préfabriquéesLinteauxTraverses en béton ou autre matériau analogue à la pierre, p. ex. avec armatures ou tirants
E04C 3/34 - ColonnesPiliersArcs-boutants en béton ou autre matériau analogue à la pierre, avec ou sans éléments de coffrage permanents, avec ou sans armature interne ou externe, p. ex. recouvrements métalliques
E21D 11/10 - Revêtement avec des matériaux de construction avec du béton coulé en placeCoffrage ou autre équipement adapté à cet effet
E04G 21/02 - Transport ou travail du béton ou de matériaux similaires susceptibles d'être mis en tas ou coulés
B28B 11/24 - Appareillages ou procédés pour le traitement ou le travail des objets façonnés pour faire prendre ou durcir
C04B 28/02 - Compositions pour mortiers, béton ou pierre artificielle, contenant des liants inorganiques ou contenant le produit de réaction d'un liant inorganique et d'un liant organique, p. ex. contenant des ciments de polycarboxylates contenant des ciments hydrauliques autres que ceux de sulfate de calcium
C04B 40/02 - Choix de l'environnement pour le durcissement
Eyedrops for ameliorating retinal circulatory disturbance and disorders associated with retinal nerve blood vessels, which contains fibrate-containing nanoparticles.
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
The present invention addresses the problem of providing a novel method and system for appropriately detecting joint status from joint acoustics. The present method is characterized by comprising: a step for acquiring, from a biological acoustics sensor, acoustic signals generated by a joint during periods including at least a first movement period when the joint changes from a first state to a second state, a joint resting period, and a second movement period when the joint changes from the second state to the first state; a step for converting the acquired acoustic signals to time trend data that at least shows the correlation between the acoustic signal intensity and time; and a step for setting the basic threshold value of the acoustic signal intensity from the time trend data, and calculating the first audio information on the basis of the basic threshold value.
An antibody or an antigen-binding fragment thereof that binds specifically to a stabilon variant. A nucleic acid that encodes the antibody or antigen-binding fragment thereof. A vector containing the nucleic acid. A peptide capable of dissociating a stabilon variant tag fusion protein from the antibody or antigen-binding fragment. A transformant containing the nucleic acid. A kit containing the antibody or antigen-binding fragment.
Provided is a pyrrole-imidazole polyamide that binds to the promoters of two or more genes and simultaneously controls transcription of the two or more genes. Also provided is a pharmaceutical composition comprising the pyrrole-imidazole polyamide. Also provided are: a pyrrole-imidazole polyamide that simultaneously controls transcription of HGF gene and TGF-β gene; a TGF-β gene expression inhibitor comprising the pyrrole-imidazole polyamide; and a pharmaceutical composition for treating a TGF-β-associated disease or a fibrous disease.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
A61P 5/00 - Médicaments pour le traitement des troubles du système endocrinien
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C08G 69/08 - Polyamides dérivés, soit des acides amino-carboxyliques, soit de polyamines et d'acides polycarboxyliques dérivés d'acides aminocarboxyliques
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
55.
NUCLEIC ACID AMPLIFICATION REACTION DEVICE PROVIDED WITH MAGNETIC BEAD STIRRING MECHANISM
The present invention addresses the problem of providing a device for more efficiently performing a nucleic acid amplification reaction using a primer fixed to a magnetic bead. The present invention provides a device for performing a nucleic acid amplification reaction in a reactor vessel accommodating a reaction reagent containing a primer oligonucleotide fixed to a magnetic bead, the device comprising: a coil that can be connected to an AC power source; and a support which is installed inside the coil and made of a thermally conductive magnetic material on which the reaction vessel can be placed, wherein the device further comprises a heater that heats the support.
A magnetized plasmoid injection device including a cylindrical external electrode, a cylindrical internal electrode coaxially disposed inside the external electrode, a plasma generating gas supply unit that supplies plasma generating gas in a pulse shape between the external electrode and the internal electrode, a magnetic field generation unit that applies a magnetic field that generates magnetized plasmoid between the external electrode and the internal electrode, a power supply control unit that applies a discharge voltage between the external electrode and the internal electrode, and an impurity generation unit that contains an impurity in the magnetized plasmoid, the impurity generation unit having a cover electrode that opens to the external electrode, a thin-rod electrode that is located inside the cover electrode and is formed of an impurity, and an impurity generation power supply that applies a voltage to the cover electrode and the thin-rod electrode.
H01J 37/32 - Tubes à décharge en atmosphère gazeuse
C23C 14/35 - Pulvérisation cathodique par application d'un champ magnétique, p. ex. pulvérisation au moyen d'un magnétron
H05H 1/16 - Dispositions pour confiner le plasma au moyen de champs électriques ou magnétiquesDispositions pour chauffer le plasma utilisant des champs électriques et magnétiques
SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION (Japon)
Inventeur(s)
Sahara, Hiroeki
Nakayama, Tomohiro
Maruo, Takuya
Abrégé
There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
The present invention addresses the problem of providing: a premix reagent for nucleic acid amplification reactions, which makes it possible to perform a nucleic acid amplification reaction in a simple manner merely by mixing the premix reagent with a specimen; and a ready-to-use nucleic acid amplification reaction kit including the premix reagent for nucleic acid amplification reactions. A nucleic acid amplification reaction kit is provided, which comprises a reaction container and a nucleic acid amplification reaction reagent contained in the reaction container, the kit being characterized in that the reagent is a multi-layered reagent premix which is cryopreserved in a layered form comprising a first reagent layer that contains a nucleic acid polymerase, a second reagent layer that contains a primer oligonucleotide, and a film that separates the first reagent layer from the second reagent layer and is composed of a substance having a solid form at a temperature of lower than 0°C and capable of being dissolved in an aqueous solution at 0 to 35°C.
A SARS-CoV-2 detection kit comprising (i) first single-stranded cyclic DNA which comprises a sequence that is complementary to a first site in a nucleic acid derived from a novel coronavirus SARS-CoV-2 and is composed of 10 to 30 nucleotides, a first primer binding sequence that is contiguous to the 5'-side of the sequence and is composed of 7 to 8 nucleotides, and a second single-stranded cyclic DNA binding sequence; (ii) a first oligonucleotide primer which comprises a sequence that is complementary to a second site contiguous to the 3'-side of the first site in the nucleic acid derived from the SARS-CoV-2 and is composed of 8 to 15 nucleotides, and a sequence that is contiguous to the 3'-side of the sequence, is complementary to the first primer binding site in the first single-stranded cyclic DNA and is composed of 7 to 8 nucleotides; (iii) second single-stranded cyclic DNA which comprises a sequence that is identical to the second single-stranded cyclic DNA binding sequence in the first single-stranded cyclic DNA and a second primer binding sequence that is contiguous to the 5'-side of the sequence; and (iv) a second oligonucleotide primer which comprises a sequence that is identical to a site contiguous to the 5'-side of the second single-stranded cyclic DNA binding sequence in the first single-stranded cyclic DNA and a sequence that is contiguous to the 3'-side of the sequence and is complementary to the second primer binding sequence in the second single-stranded cyclic DNA, in which the first oligonucleotide primer is bonded to a support through the 5'-terminal thereof, and the second oligonucleotide primer is bonded, through the 5'-terminlal thereof, to the support having the first oligonucleotide primer bonded thereto.
C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
This bone augmentation structure comprises a collagen tube and a collagen structure stored within the collagen tube. The collagen tube has a porosity of 70-98%.
A61C 8/00 - Moyens destinés à être fixés à l'os de la mâchoire pour consolider les dents naturelles ou pour y assujettir des prothèses dentairesImplants dentairesOutils pour l'implantation
This shape-memory resin composition contains: a resin (A) having a constitutional unit (a1) represented by general formula (a-1) and a constitutional unit (a2) represented by general formula (a-2); titania nanoparticles (B); and a tetraalkylphosphonium salt (C), and can be thermally melted and molded. In formula (a-1), R1is a hydrogen atom or the like. Ra1is a C1-C5 alkyl group. In formula (a-2), R2is a hydrogen atom or the like. X2is a nitrogen-containing cyclic group, a group represented by formula (a-2-1), or a group represented by formula (a-2-2). In formula (a-2-2), Ya2 is a C1-C5 alkylene group.
C08F 226/06 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison simple ou double à l'azote ou par un hétérocycle contenant de l'azote par un hétérocycle contenant de l'azote
C08L 33/14 - Homopolymères ou copolymères des esters d'esters contenant des atomes d'halogène, d'azote, de soufre ou d'oxygène en plus de l'oxygène du radical carboxyle
C08J 5/00 - Fabrication d'objets ou de matériaux façonnés contenant des substances macromoléculaires
Provided are novel determination techniques and systems enabling an AI process in which decisions are made from the viewpoint of allowing an expert to make a decision, and capable of providing a valid answer, even with a small amount of learning data, by adjusting errors in both the answer of the expert and the answer of AI. A system is configured to cause an AI process to be performed on subject training data for AI learning in which events of objects identified by identifying codes are divided into classes, and data pertaining to an object for which class determination of an event is required, and to receive class determination data obtained by the AI process. The system is configured to: cause training data for learning to be randomly input to, and learned by, each of a plurality of AI processes; input data pertaining to the object into each of the plurality of AI processes; receive from each AI process class determination data corresponding to each learning; and store the class determination data in a storage device. In this way, the class of an event of an object identified by each identifying code is determined on the basis of each class determination data item corresponding to the identifying code.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A user terminal 4 comprises: an analysis unit 42 (a chewing segment identification module 42a and a filtering/calculation module 42b) that obtains chewing information, which is chronological information indicating jaw movement for one mouthful when a user is eating; and an analysis unit 42 (analysis module 42c) that enters the chewing information to an analysis model M1 and obtains attributes for food estimated as having been chewed by a user by using jaw movement for one mouthful, output from the analysis model M1. The analysis model M1 is a trained model that has machine-learned from teaching data that includes: first information being chronological information indicating past jaw movement for one mouthful, obtained for the user; and second information indicating attributes of food chewed by the user, using past jaw movement for one mouthful.
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
A learning model provided in a segmentation device is a learning model which is generated using training data such that segmentation data of a biologically important region is output when data of a constituent maxillofacial region is input.
A spectral image generation device comprising: a light source that outputs weak light including photons having different energy; a digital micro mirror device that reflects photons output from the light source and transmits the photons through an imaging subject, reflects photons that have passed through the imaging subject, reflects photons that have been reflected by the imaging subject, or reflects photons output from the light source towards the imaging subject; a photon detector that executes processing that detects photons that have passed through the imaging subject and processing that measures the energy of those photons or processing that detects photons reflected by the imaging subject and processing that measures the energy of those photons; and a spectral image generation unit that uses the results of the processing executed by the photon detector and generates a spectral image of the imaging subject.
G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
G01N 21/27 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
The purpose of the present invention is to provide a composition that is effective for the treatment of a prototheca disease. The present invention provides a composition characterized by containing ravuconazole as an active ingredient, and being administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii.
The purpose of the present invention is to provide a composition that is effective for the treatment of a prototheca disease. The present invention provides a composition characterized by containing ravuconazole as an active ingredient, and being administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii.
Provided is a method for producing a gelatinous composition, the method including: a step for mixing lecithin that has been dissolved or dispersed in water and an organic compound (excluding lecithin) having a molecular weight of 500 or more that has been dissolved or dispersed in water to obtain a mixed liquid containing the lecithin and the organic compound; a step for freeze-drying or heat-drying the mixed liquid to obtain a solid mixture containing the lecithin and the organic compound; and a step for mixing the solid mixture, an oil component and a polar liquid to obtain a gelatinous composition. Also provided is a gelatinous composition produced using the production method.
A61K 8/02 - Cosmétiques ou préparations similaires pour la toilette caractérisés par une forme physique particulière
A61K 8/55 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant du phosphore
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
70.
DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION
SHIZUOKA PREFECTURAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kanazawa Takanori
Kosuge Yasuhiro
Miyagishi Hiroko
Suzuki Naoto
Abrégé
This drug delivery composition is for the delivery of a drug to the spinal cord; comprises a membrane-permeable peptide and a block copolymer in which a polyethylene glycol segment is linked to a hydrophobic polyester segment; and is administered nasally. This pharmaceutical composition comprises the drug delivery composition and a drug for the treatment of a spinal cord disease and is administered nasally for the treatment of a spinal cord disease.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
71.
Method for determining sensitivity to SGLT2 inhibitor and sensitivity marker for SGLT2 inhibitor
The object of the present invention is to provide a method for determining the sensitivity of a subject to an SGLT2 inhibitor, and a sensitivity marker for the SGLT2 inhibitor. The present invention provides a method for determining the sensitivity of a subject to an SGLT2 inhibitor, comprising measuring a biomarker in the biological sample of a subject, and determining the sensitivity of the subject to the SGLT2 inhibitor using the measured biomarker value as an indicator.
C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
72.
PRODUCTION METHOD AND KIT OF INDUCED PLURIPOTENT STEM CELLS
This method of producing induced pluripotent stem cells involves a step for introducing an initialization factor into somatic cells of a mammal, and culturing in a neural stem cell culture medium to obtain induced neural stem cell-like cells, and a step for cultivating said induced neural stem cell-like cells in a growth medium to obtain induced pluripotent stem cells , wherein the initialization factor contains an OCT family, a SOX family, a KLF family, a MYC family, a LIN28 family and a P53 function inhibitor.
A nucleic acid detection kit comprising (i) a first single-stranded circular DNA, (ii) a first oligonucleotide primer, (iii) a second single-stranded circular DNA and (iv) a second oligonucleotide primer, wherein the first oligonucleotide primer is attached to a carrier via the 5'-terminus thereof, and the second oligonucleotide primer is attached to the carrier, to which the first oligonucleotide primer is attached, via the 5'-terminus thereof.
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
74.
PHARMACEUTICAL USE OF RAVUCONAZOLE AS ANTI-FUNGAL FOR THE TREATMENT OF TRIAZOLES-RESISTANT CRYTOCOCCUS INFECTIONS
The purpose of the present invention is to provide an anti-fungal agent effective for cryptococcosis. The present invention provides an anti-fungal agent containing ravuconazole as an active ingredient, the anti-fungal agent being characterized by being administered to an animal with cryptococcosis. The present invention also provides an anti-fungal agent containing ravuconazole as an active ingredient, the anti-fungal agent being characterized by being administered to an animal infected by Cryptococcus neoformans having resistance against a triazole-based antibacterial agent selected from the group consisting of fluconazole, itraconazole, and voriconazole.
A01N 57/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques du phosphore comportant des liaisons phosphore-oxygène ou des liaisons phosphore-soufre contenant des radicaux hétérocycliques
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
The purpose of the present invention is to provide an anti-fungal agent effective for cryptococcosis. The present invention provides an anti-fungal agent containing ravuconazole as an active ingredient, the anti-fungal agent being characterized by being administered to an animal with cryptococcosis. The present invention also provides an anti-fungal agent containing ravuconazole as an active ingredient, the anti-fungal agent being characterized by being administered to an animal infected by Cryptococcus neoformans having resistance against a triazole-based antibacterial agent selected from the group consisting of fluconazole, itraconazole, and voriconazole.
SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION (Japon)
Inventeur(s)
Sahara, Hiroeki
Nakayama, Tomohiro
Maruo, Takuya
Abrégé
The present invention improves the effect of radiotherapy. This radiosensitizer for treating cancer contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the radiosensitizer being characterized by being used so that a compound represented by general formula (I) is administered to a patient in an amount of 8 mg/kg or less per dose. This radiosensitizer is also characterized by being used to repeat a set of the administration of the radiosensitizer and the irradiation with radiation immediately after the administration so that the total irradiation dose of radiation with respect to cancer is 10 Gy or greater.
The present invention is to provide a tissue slice selection method and an embedded block-preparing cassette which are capable of suppressing occurrence of errors in inspection results. The present invention makes it possible to suppress the occurrence of errors in inspection results by including: an embedded block-preparing process of preparing an embedded block by embedding both a biological tissue fragment and a standard substance in the same embedding agent; an embedded tissue slice preparing step of slicing the embedded block to prepare a sheet-like embedded tissue slice having a tissue slice and standard substance slices appearing on a surface thereof; and a tissue slice selecting step of selecting the tissue slice to be inspected, based on a light signal from the standard substance slice.
G01N 1/36 - Enrobage ou montage analogue d'échantillons
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
A magnetized plasmoid injection device (10) which enables the precise control of the amount of impurities, and which is provided with: a cylindrical external electrode (11); an internal electrode (12) which is coaxially arranged within the external electrode; a plasma generating gas supply unit (13) which supplies a plasma generating gas in a pulse state between the external electrode and the internal electrode; a magnetic field generation unit (15) which applies a magnetic field that generates a magnetized plasmoid between the external electrode and the internal electrode; a power supply control unit (14) which applies a discharge voltage between the external electrode and the internal electrode; and an impurity generation unit (100) which has the magnetized plasmoid contain impurities. The impurity generation unit comprises: a cover electrode (102) which opens to the external electrode; a needle-like electrode (101) which is positioned within the cover electrode, while being composed of impurities; and an impurity generating power supply which applies a voltage to the cover electrode and the needle-like electrode.
H05H 1/16 - Dispositions pour confiner le plasma au moyen de champs électriques ou magnétiquesDispositions pour chauffer le plasma utilisant des champs électriques et magnétiques
G21B 1/05 - Réacteurs de fusion thermonucléaire avec confinement magnétique ou électrique du plasma
G21B 1/11 - Réacteurs de fusion thermonucléaire Détails
C23C 14/22 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le procédé de revêtement
A three-dimensional printing apparatus (1) allowing a linear filament (F) in which a fiber bundle (C) is impregnated with resin (P) to be continuously ejected includes twisting means (6) for allowing a total amount of twisting of the filament (F) or an amount of twisting of the fiber bundle (C) to be changed.
B33Y 30/00 - Appareils pour la fabrication additiveLeurs parties constitutives ou accessoires à cet effet
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
3 is, identically or differently in each occurrence, selected from hydrogen and an optionally substituted aliphatic hydrocarbon group; and n represents an integer of 1 or more.
The invention provides a novel polymer, a composition, and a molded article. The polymer contains a constitutional unit represented by the following formula (1):
11 is a hydrogen atom or an alkyl group optionally containing a fluorine atom; and a is an integer of 1 to 4.
C08G 77/52 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant du silicium, avec ou sans soufre, azote, oxygène ou carbone dans lesquels au moins deux atomes de silicium, mais pas la totalité, sont liés autrement que par des atomes d'oxygène par des liaisons au carbone contenant des cycles aromatiques
C08L 27/18 - Homopolymères ou copolymères du tétrafluoro-éthylène
C09K 3/10 - Substances non couvertes ailleurs pour sceller ou étouper des joints ou des couvercles
82.
COMPOUND, DISPERSANT, COMPLEX, DISPERSION, AND METHOD FOR PRODUCING COMPLEX
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (Japon)
NIHON UNIVERSITY (Japon)
FUKUI FIBERTECH CO., LTD. (Japon)
AISIN SEIKI KABUSHIKI KAISHA (Japon)
KYOWA INDUSTRIAL CO., LTD. (Japon)
Inventeur(s)
Ishikawa Takashi
Ichiki Makoto
Fukui Eisuke
Hirayama Norio
Sakata Kazuhiro
Hirabayashi Akiko
Abrégé
A production device 10 for fiber-reinforced thermoplastic resin comprising: an impregnation chamber for impregnating a thermoplastic resin monomer liquid or solution into a plurality of long fibers 20; a polymerization chamber 11 for polymerizing the monomer by heating the long fibers 20 that are impregnated with the monomer; and a moving unit 16 for drawing the long fibers 20 impregnated with the thermoplastic resin from the chamber.
B29K 77/00 - Utilisation de polyamides, p. ex. polyesteramides, comme matière de moulage
B29K 105/08 - Présentation, forme ou état de la matière moulée contenant des agents de renforcement, charges ou inserts de grande longueur, p. ex. ficelles, mèches, mats, tissus ou fils
A61B 1/24 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour la bouche, c.-à-d. stomatoscopes, p. ex. portant des abaisse-langueInstruments pour ouvrir la bouche ou la maintenir ouverte
A61C 19/04 - Instruments de mesure spécialement adaptés à la technique dentaire
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61C 1/08 - Éléments de machines spécialement adaptés à la chirurgie dentaire
85.
Medical x-ray CT imaging apparatus, medical x-ray ray CT imaging condition setting method, and non-transitory computer readable medium
A medical X-ray CT imaging apparatus includes an X-ray generator that generates a cone beam, an X-ray detector, a support that supports the X-ray generator and the X-ray detector while the X-ray generator and the X-ray detector are opposed to each other, a turning drive unit that turns the X-ray generator and the X-ray detector, which are supported by the support, an imaging information receiving unit, and an X-ray output condition setting unit. The imaging information receiving unit receives an imaging area setting relating to at least one of a size of an imaging area, an imaging purpose, and an imaging region. The X-ray output condition setting unit automatically sets an output condition of the X-ray generator according to at least one of the size of the imaging area, the imaging purpose, and the imaging region, which are received by the imaging information receiving unit.
A61B 6/14 - Applications ou adaptations à l'art dentaire
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A first position setting unit receives an operation to designate a position in a mesiodistal on a panoramic tomographic image displayed on a display, and sets a first position on a curved section based on the designation operation. The fluoroscopic imaging information providing unit provides information irradiating a subject with an X-ray beam along a direction having a component of a tangential direction at the first position of the curved section to execute fluoroscopic imaging acquiring a fluoroscopic image to a main body. A second position setting unit receives an operation to designate a position in a buccolingual direction on the fluoroscopic image displayed on the display, and sets a second position in the buccolingual direction based on the designation operation.
A61B 6/14 - Applications ou adaptations à l'art dentaire
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 6/10 - Moyens de sécurité spécialement adaptés à cet effet
Provided are a tissue slice selection method and an embedded block preparing cassette with which it is possible to suppress the occurrence of errors in inspection results. This tissue slice selection method makes it possible to suppress the occurrence of errors in inspection results by comprising: an embedded block preparing step of preparing an embedded block 24 by embedding a biological tissue piece 22 and a reference material 21 in the same embedding agent 23; an embedded tissue slice preparing step of thinly cutting the embedded block 24 to prepare a sheet-like embedded tissue slice 44 in the surface of which a tissue slice 42 and a reference material slice 41a, 41b, 41c, 41d, 41e appear; and a tissue slice selecting step of selecting the tissue slice 42 to be inspected, on the basis of an optical signal from the reference material slice.
Provided is a preparation which has an effect of promoting the healing of a tissue wound. The wound healing promoter according to the present invention comprises, as an active ingredient, at least one member selected from among a compound represented by formula (1), a salt thereof and a hydrate of the same. In formula (1): R1 and R2 are either the same or different and represent a hydrogen atom or a hydrocarbon group optionally having one or more substituents selected from the group consisting of a halogen atom, -COOR3, -CONR32, -COR3, -CN, -NO2, -NHCOR3, -OR3, -SR3, -OCOR3, -SO3R3 and -SO2NR32 (wherein R3's are either the same or different and represent a hydrogen atom or an optionally substituted aliphatic hydrocarbon group); and n is an integer of 1 or greater.
This score determination device of a medical examination for biological function is provided with: a weight calculation unit which calculates a weight on the basis of first data including, among data about a first subject, at least one among data that includes a determination score of a medical examination based on the subject's own report and indicates an examination result of the medical examination, and data that indicates a physical feature; and a score determination unit which determines a determination score of a second subject on the basis of the weight calculated by the weight calculation unit, and second data including, among data about the second subject, at least one among data which indicates an examination result of a medical examination and data which indicates a physical feature.
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
91.
TEMPERATURE-RESPONSIVE HYDROGEL AND METHOD FOR PRODUCING SAME
[Problem] To provide a temperature-responsive hydrogel by means of a simple method (mixing), said temperature-responsive hydrogel having a feature such that the viscosity thereof is high at high temperatures but low at low temperatures. [Solution] It is found that a temperature-responsive hydrogel which has high viscosity at high temperatures and low viscosity at low temperatures, while having a high (viscosity at high temperatures)/(viscosity at low temperatures) ratio, is able to be obtained by a method for mixing an aqueous solution containing a polyalkylene glycol (A) that has a weight average molecular weight of from 20,000 to 10,000,000 and an aqueous solution containing a silicate (B) within a specific component composition range, specifically at a mass concentration of A of 0.01-1.5% by mass, preferably at a mass concentration of A of 0.1-0.4% by mass and at a mass concentration of B of 0.5-10% by mass, preferably at a mass concentration of B of 1-5% by mass, with the mass ratio R of A to B (R = (mass of A)/(mass of B)) being within the range of from 0.01 to 0.5; and this finding led to the completion of the present invention.
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
A three-dimensional printing apparatus (1) capable of continuously ejecting a linear filament (F) in which a fiber bundle (C) is impregnated with resin (P) is provided with twisting means (6) capable of changing the overall amount of twisting of the filament (F) or a twisting amount of the fiber bundle (C).
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
B33Y 30/00 - Appareils pour la fabrication additiveLeurs parties constitutives ou accessoires à cet effet
D02G 3/44 - Filés ou fils caractérisés par la destination pour laquelle ils ont été conçus
Conventional reverse photochromic compounds have difficulty in sensing light in a visible light region of 600 nm or more used in medical applications, etc. The present invention addresses the problem of providing a reverse photochromic compound and polymer which are highly sensitive even to light of 600 nm or more. The present invention pertains to a compound or the like represented by general formula (1) (wherein, R1 and R4 each independently represent a hydrogen atom or the like, R2, R3, and R5 each independently represent an alkyl group or the like, R6 represents a group having a polymerizable unsaturated group, a carboxy group, an alkoxycarbonyl group, or the like, R31 and R32 each independently represent an alkoxy group or the like, R33 and R34 each independently represent a hydrogen atom or the like, Y1 represents an oxygen atom or a sulfur atom, An- represents an anion, n1-n3 represent a specific integer, and R1 and R2, R3 and R4, and/or R33 and R34 may form an alkylene group.)
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C08F 20/36 - Esters contenant de l'azote contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle
The present invention provides a novel polymer, a composition, and a molded article. This polymer has a structural unit represented by general formula (1) (in the formula, X11 and X12 may be the same or different from each other, and each represent a hydrogen atom, an alkyl group optionally having a fluorine atom, or a phenyl group, Y11 represents an oxygen atom or a sulfur atom, Rf11 represents a hydrogen atom or an alkyl group optionally having a fluorine atom, and a represents an integer of 1-4).
C08G 77/52 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant du silicium, avec ou sans soufre, azote, oxygène ou carbone dans lesquels au moins deux atomes de silicium, mais pas la totalité, sont liés autrement que par des atomes d'oxygène par des liaisons au carbone contenant des cycles aromatiques
C08L 83/14 - Compositions contenant des composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant uniquement du silicium, avec ou sans soufre, azote, oxygène ou carboneCompositions contenant des dérivés de tels polymères dans lesquels au moins deux atomes de silicium, mais pas la totalité sont liés autrement que par des atomes d'oxygène
C08L 101/04 - Compositions contenant des composés macromoléculaires non spécifiés caractérisées par la présence de groupes déterminés contenant des atomes d'halogènes
C09K 3/10 - Substances non couvertes ailleurs pour sceller ou étouper des joints ou des couvercles
H01L 21/3065 - Gravure par plasmaGravure au moyen d'ions réactifs
95.
DISEASE CONDITION DETERMINATION DEVICE, DISEASE CONDITION DETERMINATION SYSTEM, AND DISEASE CONDITION DETERMINATION PROGRAM
The disease condition determination device according to the present invention is provided with: a first separation degree calculation unit for calculating a degree of separation on the basis of first load blood flow information which is blood flow information for a task state in which a first load for varying the blood flow state of a subject is imposed on the subject, and second load blood flow information which is blood flow information for a control state in which a second load different from the first load is imposed on the subject, from among blood flow information obtained by measuring blood flow in the brain of a subject by optical measurement using near-infrared rays; an oscillation detection unit for detecting oscillation in variation of the hemoglobin concentration of the blood flow of the subject on the basis of non-load blood flow information; a phase detection unit for detecting the phase of the variation in hemoglobin concentration of the blood flow of the subject on the basis of the non-load blood flow information; and a determination unit for determining the disease condition of the subject on the basis of the degree of separation calculated by the first separation degree calculation unit, the oscillation detected by the oscillation detection unit, and the phase detected by the phase detection unit.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
96.
Device for calculating construction assistance information, system for calculating construction assistance information, and program
A device for calculating construction assistance information includes: an acquisition unit that acquires, from a vibratory hammer construction machine, information that contains at least values indicating a eccentricity force of a vibratory hammer which the vibratory hammer construction machine imparts to a construction object, the number of impacts, and a depth of penetration of the construction object; and a calculation unit that calculates a accumulated impact force indicating a work load of construction on the basis of the information acquired by the acquisition unit.
An oligonucleotide selected from the group consisting of the following oligonucleotides (i) to (iii): (i) an oligonucleotide which comprises the nucleotide sequence represented by SEQ ID NO: 15; (ii) an oligonucleotide which comprises a nucleotide sequence produced by deleting, substituting or adding one or several residues in the nucleotide sequence represented by SEQ ID NO: 15 and which has a binding ability specific to ITS2 of Aspergillus terreus; and (iii) an oligonucleotide which comprises a nucleotide sequence complementary to the nucleotide sequence for the oligonucleotide (i) or (ii).
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A dental caries diagnosis device comprising a light source which emits examination light (R), and a light receiving unit (4f) which receives the examination light (R) with which a tooth has been irradiated comprises: a head-side casing (4a1) which is inserted into the mouth in a contactless manner with respect to the tooth or the gum, and which projects the examination light (R) toward the tooth; and a filter (4e) which is disposed in front of the light receiving unit (4f) and which removes a noise component from the received light, wherein the light receiving unit (4f) receives the examination light (R) that has been transmitted through the tooth.
A61B 1/24 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour la bouche, c.-à-d. stomatoscopes, p. ex. portant des abaisse-langueInstruments pour ouvrir la bouche ou la maintenir ouverte
A61C 19/04 - Instruments de mesure spécialement adaptés à la technique dentaire
100.
PERIODONTITIS TEST KIT USING MIRNA AS MARKER, AND TEST METHOD
Since a miRNA that serves as a diagnostic marker for periodontitis of the present invention displays a change specific to periodontitis, diagnosis of periodontitis can be performed accurately.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques